YTHDF2 was frequently overexpressed in AML, and the m6A modified apoptosis-induced gene TNFRSF2 was targeted by YTHDF2 to decrease its half-life, which was identified as a unique therapeutic target [42]. This evidence concerns the gene YTHDF2 and acute myeloid leukemia.